Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia

NCT04154709 is registered in ClinicalTrials.gov with Kai Lin Xu; Jun Nian Zheng as lead sponsor.

NCT NCT04154709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04154709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia
Lead sponsor
Kai Lin Xu; Jun Nian Zheng
Phase
Phase 1
Overall status
Unknown status
Start date
December 10, 2019
Completion date
June 30, 2022
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia